ERBB2 and neoplasm: Anti-PD-L1 plus GD2-EATs or HER2-EATs improved tumor control compared to EATs alone (P = 0.0257 for GD2-EATs and P = 0.0374 for HER2-EATs), while combination with anti-PD-1 failed to improve the anti-tumor response compared to GD2-EATs or HER2-EATs alone (P = 0.1969 and P = 0.7894, respectively).